Metastatic Solid Tumors
Conditions
Brief summary
A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of SKB107 in subjects with advanced solid tumors with bone metastases.
Detailed description
This study is a multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of SKB107 in subjects with advanced solid tumors with bone metastases. The study is divided into two parts: Phase Ia and Phase Ib. The Phase Ia study is the dose escalation phase. The primary objective is to assess the safety and tolerability of a single administration of SKB107 and to determine the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) based on the occurrence of Dose-Limiting Toxicities (DLTs) associated with SKB107 (if the MTD cannot be determined).The Phase Ib study is the dose expansion phase. The primary objective is to explore the optimal dose, safety, or efficacy of SKB107 at a selected dose level (confirmed as safe by the Safety Review Committee (SRC) and not exceeding the MTD or MAD)
Interventions
DRUGSKB107 for injection
177Lu-DOTA-IBA is a Radionuclide conjugated drugs (RDC) targeting bone.
Sponsors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. The age should be between 18 years and 75 years at the time of signing the informed consent form (ICF); 2. The Eastern Cooperative Oncology Group (ECOG) performance status score should be ≤ 1; 3. The expected survival period should be ≥ 3 months; 4. Phase Ia: Subjects with advanced solid tumor bone metastases diagnosed by histology or cytology; and the subjects have failed standard treatment, or have no standard treatment, or are intolerant or not applicable to standard treatment; 5. Phase Ib: Subjects with advanced mCRPC diagnosed by histology or cytology; 6. Before the first administration, a 99mTc-MDP bone scan diagnosed multiple bone metastases, and at least one site was confirmed by CT or MRI; 7. Have adequate organ and bone marrow functions; 8. For subjects with reproductive capacity, take effective medical contraceptive measures during the study treatment and within 6 months after the last administration; 9. The subjects voluntarily join this study, sign the informed consent form, and can comply with the visit and related procedures stipulated in the protocol.
Exclusion criteria
1. The washout period before the first administration of the study drug was insufficient. 2. Previous received similar radionuclide internal irradiation treatment. 3. Previous received or planned to receive during the study period semi-body external radiotherapy targeting bone metastases. 4. Known "super bone imaging". 5. Known spinal cord compression, or clinical imaging manifestations suggesting impending spinal cord compression. 6. Any cardiovascular or cerebrovascular diseases or cardiovascular risk factors that may affect the treatment of the study drug. 7. Poorly controlled diabetes and hypertension. 8. The toxicity of previous anti-tumor treatment before the first administration has not recovered to ≤ 1 grade (evaluated based on NCI-CTCAE v5.0) or has not reached the level specified in the inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0. | Up to 3 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum plasma concentration (Cmax) of SKB107 | Up to 1 week | — |
| Dosimetry | Up to 1 week | To collec the biological distribution of major tissues/organs. |
| Time to Radiographic Bone Progresion (TTRBP) | Through study completion, an average of 1 year. | Time from start of treatment to progression of bone lesion (PD) or death, whichever occurs first, during the study period |
| Radiographic progression-free survival (rPFS) | Through study completion, an average of 1 year | Time from start of treatment to progression of Disease (PD) or death, whichever occurs first |
| Overall survival(OS) | Up to 3 years | Time from start of treatment to death due to any reason |
| symptomatic skeletal event-free survival (SSE-FS) | Up to 3 years | Time from start of treatment to the first occurrence of new SSE or death from any cause , whichever occurs first. |
Countries
China
Contacts
CONTACTYina Diao
Outcome results
None listed